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ABSTRACT
Combinations of conventional chemotherapeutics with unconventional anticancer agents such as reactive 
oxygen and nitrogen species may offer treatment benefits for cancer therapies. Here we report a novel 
polymeric platform combining the delivery of Doxorubicin (DOXO) with the light-regulated release of nitric 
oxide (NO). An amphiphilic block-copolymer (P1) was designed and synthesized as the drug carrier, with 
pendant amine groups to attach DOXO via a urea linkage and a NO photodonor (NOPD) activable by visible 
light. The two grafted-copolymers (P1-DOXO and P1-NOPD) self-assembled via solvent displacement 
methods into nanoparticles (NPs), containing both therapeutic components (NP1) and, for comparison, the 
individual NOPD (NP2) and DOXO (NP3). All the NPs were fully characterized in terms of physicochemical, 
photochemical and photophysical properties. These experiments demonstrated that integration of the NOPD 
within the polymeric scaffold enhanced the NO photoreleasing efficiency when compared with the free 
NOPD, and that the proximity to DOXO on the polymer chains did not significantly affect the enhanced 
photochemical performance. Internalization of the NPs into lung, intestine, and skin cancer cell lines was 
investigated after co-formulation with Cy5 fluorescent tagged polymers, and cytotoxicity of the NPs against 
the same panel of cell lines was assessed under dark and light conditions. The overall results demonstrate 
effective cell internalization of the NPs and a notable enhancement in killing activity of the dual-action 
therapeutic NP1 when compared with NP2, NP3 and the free DOXO, respectively. This suggests that the 
combination of DOXO with photoregulated NO release, achieved through the mixed formulation strategy of 
tailored polymer conjugate NPs, may open new treatment modalities based on the use of NO to improve 
cancer therapies.
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INTRODUCTION
Multimodal cancer therapy involves the use of two or more treatment modalities with the aim to attack 
tumors by acting either on a single oncogenic pathway through different mechanisms or across parallel 
pathways without amplification of side effects.1-7 In this regard, the combination of conventional 
chemotherapeutics with light-activated release of oxidizing agents such as reactive oxygen and nitrogen 
species (ROS and RNS) may open new routes to better therapies.8 Light is a minimally invasive tool that 
permits the introduction of a cytotoxic burst in biological environments with high spatiotemporal control.9 
Among the light activatable therapeutic treatments, photodynamic therapy (PDT) is so far one of the most 
promising to combat cancers.10 PDT is based on the catalytic photogeneration of the highly reactive singlet 
oxygen (1O2) through appropriate photosensitizers (PSs) and combinations of PDT with chemotherapy have 
been successfully demonstrated for multimodal cancer treatments.11 Another emerging light-activated 
approach is based on the photoregulated release of nitric oxide (NO) through the use of NO photodonors 
(NOPDs).12-16 Although still confined to the research area, NO-based PDT, namely NOPDT, has very promising 
features for cancer treatment.17 In fact, nitric oxide (NO), apart from playing multiple roles in the 
bioregulation of a broad array of physiological processes,18 has also proven to play a key role in cancer 
biology.19 This diatomic radical is a multitarget species able to attack proteins, lipids and DNA, does not incur 
multi-drug resistance (MDR) and, in view of its short lifetime (ca. 5 s in tissues) is confined to a tightly-defined 
region of action, reducing systemic off-target effects typical of many conventional drugs. However, the 
biological effects of NO in cancer are strictly dependent on its concentration.19 For example, low levels of NO 
(in the pM-nM concentration range) inhibit apoptosis.20 On the other hand, high levels of NO (M 
concentration range) promote apoptosis directly through nitrosylation of crucial mitochondrial enzymes,21-22 
or indirectly, via oxidative and nitrosative stress resulting from the formation of RNS.23 Furthermore, in a 
concentration range not sufficient either to inhibit or encourage apoptosis, NO has been revealed to be very 
effective in inhibiting the ATP Binding Cassette (ABC) transporters, which in turn regulate the efflux of 
chemotherapeutics and induce multidrug resistance (MDR) in cancer cells.24-25 For such reasons, the NOPDs 
are more appealing as therapeutic agents rather than NO precursors releasing NO upon thermal, enzymatic 
or metabolic stimuli.26-27 In fact, NOPDs allow NO dosage to be controlled with great accuracy by tuning the 
duration and intensity of the irradiation. In contrast to PDT, the working principle of NOPDT is not catalytic 
as it exploits the excitation light to uncage NO leading to a consumption of the NOPD.12-16 However, since NO 
photorelease is independent of O2 availability, NOPDT offers the great advantage to successfully complement 
PDT at the onset of hypoxic conditions, typical for some tumours, where PDT may otherwise fail.28 This has 
made combinations of NOPDT with conventional PDT a subject of much investigation in recent years.29 
However, there are surprisingly limited examples in which the combination of NOPDT with 
chemotherapeutics have been reported to date.30
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Doxorubicin (DOXO) is one of the most widely-adopted anticancer drugs among anthracycline derivatives,31 
however, its effectiveness is limited by a series of resistance mechanisms that usually occur regardless of the 
nature of the tumor. In a resistance condition, the energy-dependent drug efflux pumps (i.e., P-gp, MDR-
related protein 1 and breast cancer resistance protein) actively efflux DOXO from the cells, hence, reducing 
its pharmacological potential. We have recently demonstrated the successful combination of NOPDs with 
DOXO as a suitable strategy to fight MDR, increasing the intracellular accumulation of DOXO, enhancing its 
activity and significantly reducing its active concentration.30 Despite the current clinical standards of “cocktail 
administrations” using combinations of drugs, in the case of an antineoplastic agent with NOPD, there are 
significant pharmacokinetic and pharmacodynamic limitations as a result of the distinctive physiological fates 
and non-uniform distribution of the free drugs. Accordingly, the development of nanocarrier materials, in 
which multiple therapeutic cargoes can be entrapped in a single nanoparticle agent, is a promising approach 
for synchronizing and optimizing the location, timing and duration of combination drug release.32-33 Polymer 
conjugates in particular offer many possibilities for precise and controlled delivery of multiple therapeutics 
in the same area of the body and at predefined extra/intracellular levels.34-35 In this context, we have recently 
reported the synthesis of biodegradable block copolymers containing polyethylene glycol, lactide and a 
functionalized protected cyclic carbonate, which self-assemble into nanoparticles (NPs) and which can be 
functionalized with “active” molecules, such as DOXO.36 We hypothesized that the anticancer performance 
of DOXO might be enhanced by exploiting the photoregulated release of NO, and describe herein a multi-
component (NOPD-DOXO) polymeric platform which can be assembled by a simple formulation strategy. In 
the present work, we describe the synthesis, characterization and biological evaluation of these materials in 
lung, intestinal and skin cancer cell lines, and show their improved efficacy compared to the individual 
components.
RESULTS and DISCUSSION
Polymeric platform: synthesis and characterization. The block copolymer platform used as a drug carrier 
has been previously described.36 Methoxy-polyethylene glycol with molecular weight 5000 Da (mPEG5000) was 
used to initiate Ring-Opening Polymerisation (ROP) of co-monomers lactide (LA) and an in-house prepared 
cyclic carbonate bearing a tert-butoxycarbonyl (BOC)-protected amine, named tert-butyl (2-oxo-1,3-dioxan-
5-yl) carbamate (referred as tBSC) with 1,8-diazabicyclo[5.4.0]undec-5-ene, (DBU)37 as a catalyst. The final
block ratio achieved was mPEG5000:(LA):(tBSC) 1:(50):(50) while the resulting architecture was linear. The
subsequent conjugation of mPEG5000-(LA)50-(tBSC)50, named P1, with the drugs of our interest, NOPD and
DOXO, was performed through two steps, as shown in Scheme 1A-C. The reaction conditions of both steps
were previously optimised:36 initially, the BOC-deprotection was carried out via TFA hydrolysis (Scheme 1A)
and subsequently, the conjugation of partly deprotected mPEG5000-(LA)50-(tBSC)50, named P1*, with the
"active" molecule (DOXO or NOPD) utilized N,N’-disuccinimidyl-carbonate (DSC) coupling (Scheme 1).
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Therefore, two grafted-copolymers P1-NOPD (Scheme 1B) and P1-DOXO (Scheme 1C) were produced by a 
similar synthetic strategy with the only difference in reaction conditions being the solvents used, i.e. 
acetonitrile for P1-NOPD and a mixture of DMSO/acetonitrile, 50/50, v/v for P1-DOXO. The units estimated 









































































































Scheme 1. Reagents and conditions: A) BOC-deprotection. i) TFA, DCM, 0 °C. B) Synthesis of P1-NOPD. ii) DSC, 
TEA, CH3CN, 0 °C; iii) P1*, TEA, CH3CN, 0 °C. C) Synthesis of P1-DOXO. iv) DSC, TEA, DMSO/CH3CN, 0 °C; v) P1*, 
TEA, DMSO/CH3CN, 0 °C.
The choice of using an NOPD based on a nitroaniline-derivative chromophore reported in Scheme 1 was 
previously developed in our group,38-39 and has been successfully integrated in a variety of nanoconstructs 
and presents the following advantages:40 i) excellent dark stability and NO release exclusively controlled by 
illumination with visible light; ii) chemical derivatization by simple synthetic procedures; iii) absorption 
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spectrum which does not significantly overlap the absorption of DOXO, allowing the selective excitation of 
the NOPD with blue light and its easy quantification as well as that of DOXO by spectrophotometric analysis; 
iv) lack of fluorescence emission, which precludes any potential quenching by DOXO via Forster Resonance
Energy Transfer (FRET) once confined in the close proximity (i.e., within the same NP).
Nanoparticles assembly and characterization. The ability of the two grafted-copolymers (P1-NOPD and P1-
DOXO) and the bare polymer P1 to self-assemble into NPs was evaluated,41 using nanoprecipitation as the 
standard formulation technique. In particular, a mixed micelles strategy was applied,42 in which P1 and the 
polymer prodrugs were co-precipitated alternatively in various combinations as described in Figure 1. 
Consequently, the formulation NP1 was a mixed, kinetically trapped, micelle-like nanoparticle and was 
formed by P1-NOPD and P1-DOXO in equal ratio. The other micelle-like NPs were NP2, consisting of P1-NOPD 
and bare polymer P1 in equal ratio; NP3, with P1-DOXO and P1 and finally, NP4 which constituted only of the 
bare polymer backbone without a drug or NO-photodonor. This strategy was thus a simple tool to assemble 
combination therapy NPs using the same polymeric backbone across all the mixed micelles formulations.37
Figure 1. Schematic illustration of NPs 1-4.
As reported in Table 1, the NPs sizes measured by DLS ranged from 43 to 110 nm, indicating that these were 
kinetically-trapped species and not ‘classical’ micelles in that the diameters were much greater than those 
expected from the likely chain lengths of the individual polymers. The smallest micelles were those of NP4 
while the largest was NP1, most likely due to the reduced ability to pack side-chains containing both NOPD 
and DOXO in the NP1 aggregates compared to the ‘bare’ polymer chains in NP2. Also the zeta potential of all 
NPs (Table 1) were negative, ranging from -25 to -14 mV, as expected based on the presence of a hydrophilic 
PEG corona shell and the weak lone-pair cation interactions at the oxyethylene units and the corresponding 
association of anions to form the outer layers.36,41 Interestingly, the smallest micelles had the least negative 
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zeta potential (ca. -14 mV) while the NP1 formulations presented the most negative zeta potential value (ca. 
-25 mV), likely indicative of a more expanded PEG corona in the combination micelle-like aggregates. The
NPs were stable in biological media (Figure S1).
NP Size ± S.D. (nm) Zeta potential ± S.D. (mV) PDI
1 110 ± 10 -25 ± 1 0.242
2 72 ± 7 -20 ± 4 0.111
3 78 ± 3 -19 ± 1 0.132
4 43 ± 5 -14 ± 3 0.092
Table 1. Size, zeta potential and polydispersity index (PDI) of NPs 1-4 at 50 µg/mL.
The DOXO or/and NOPD content in each micelle (NP1-3) was evaluated via fluorescence or UV detection 
respectively, and using free DOXO (λexc= 490 nm, λem= 553 nm) and NOPD (λmax= 405 nm) as the standard 
solutions. The amounts of the “active” molecules (DOXO and/or NOPD), expressed as µg/mL, are reported in 
Table 2. 
NP DOXO ± S.D. (µg/mL) NOPD ± S.D. (µg/mL)
1 23.1 ± 2 14.8 ± 1
2 - 28.4 ± 2
3 14.6 ± 1 -
Table 2. NOPD or/and DOXO content in NPs 1-3.
Spectroscopic and photochemical characterization of the NPs. Figure 2A shows the absorption spectrum of 
NP1 and, for sake of comparison that of the free NOPD and DOXO in water medium. The spectral features 
reflect the presence of both components in the NPs with the absorption of the NOPD dominating in the blue 
region and the weaker absorption due to the DOXO in the green region beyond 500 nm. Note that, the 
absorption maximum of the NOPD in the NPs is blue-shifted of ca. 10 nm in comparison to the free NOPD in 
the same solvent. Since such a shift was also observed in the case of NP2, which did not contain DOXO (see 
Figure S2), it cannot be ascribed to an interaction between the two chromogenic components in the NPs. 
Rather, in view of the strong push-pull character of the absorption band of the NOPD, which is strongly 
dependent on the solvent polarity, the shift observed suggests that the NOPD was mainly exposed to a less 
hydrophilic environment (i.e. the inner part of the NPs). Due to the scattering of the NPs, the lower content 
of DOXO and its low extinction coefficient, compared with the NOPD, it is difficult to gain insights into spectral 
modification of this component upon binding with the NPs by absorption spectroscopy. Exploiting the 
fluorescence of DOXO, we then inspected the static and dynamic behaviour of NP1 compared with an 
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optically matched solution of free DOXO. As reported in Figure 2B, the fluorescence emission efficiency and 
maxima position of NP1 was very similar to that of the free fluorophore in the same solvent. In addition, the 
biexponential decay of the free DOXO was only slightly affected upon its binding with the NPs.  These results 
provided evidence that the DOXO-rich regions experienced mainly a hydrophilic environment, as supported 
by the more negative values of the zeta potential found for NP1 (vide supra), and again suggested that these 
were not sharp core-shell micelles, but trapped aggregates as depicted in the schematics of Figure 1. 







































Figure 2. (A) Absorption spectrum of NP1 (a) and of the equal amounts of free NOPD (b) and DOXO (c) in 
water. (B) Fluorescence emission spectra (exc = 490 nm) of NP1 (a) and of an optically matched solution of 
free DOXO (b) in water. The inset shows the fluorescence decay and the related bi-exponential fitting for 
solutions of NP1 (a) and the free DOXO (b); trace c is the prompt signal. λexc = 455 nm; λem = 590 nm.
A key requisite for any photoactivatable compound after its integration into appropriate materials, or if used 
in conjunction with other chromophoric components located in close proximity (i.e. NOPD and DOXO), is the 
preservation of its photochemical properties. This is an important distinction compared to non-
photoresponsive compounds and is not trivial. In most cases, the response to light of the single photoactive 
units can be significantly affected in nature, efficiency or both by the occurrence of competitive, undesired 
photoprocesses (i.e., photoinduced energy and/or electron transfer, non-radiative deactivation, etc.), which 
do not allow the photoactivatable components to work independently upon light absorption and therefore 
preclude the final goal.32-33 In our case, the non-emissive behaviour of the NOPD helps to avoid any potential 
quenching by DOXO via FRET mechanism. Besides, the localization of the NOPD and DOXO in different 
environments of the NPs was expected to significantly reduce any dynamic quenching process (i.e. energy 
transfer via Dexter mechanism or photoinduced electron transfer). 
NO photorelease from NP1, and for comparison NP2, was monitored directly and indirectly through an 
amperometric technique using an ultrasensitive NO electrode and the Griess assay, which detects the 
content of nitrite in solution (the main oxidation product of NO), respectively. Figure 3A shows that NO 
generation in the micromolar range was exclusively achieved upon visible light excitation, stopped as the 
light was turned off and restarted when the light was turned on again. Interestingly the NO photogeneration 
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in the NP samples was more than one order of magnitude larger than that observed in aqueous solution for 
the free NOPD.38 This result is in excellent agreement to what we recently observed for NOPDs based on the 
same chromogenic unit entrapped in micellar,43 calixarene44 and polymeric nanoassemblies.45 It is likely that 
this was due to the low polarity environment experienced by the NOPD (vide supra) combined with the 
presence of easily abstractable hydrogens close to the phenoxy-radical intermediate involved in the 
mechanism of the NO photorelease.43-45 It is also worth noting that photoexcitation of the NOPD does not 
lead to any additional photochemical pathways competitive with the NO photorelease. In fact, as illustrated 
in Figure 3B, the spectral changes observed upon irradiations showed a very clear bleaching of the main 
absorption band of the NOPD, in excellent agreement with the formation of a phenol derivative, absorbing 
in the UV region, as the sole stable product formed after the NO photogeneration.38 The slight difference 
observed in the NO photorelease for the two samples was also confirmed by a Griess assay (Figure S3). This 
was due to a different fraction of absorbed photons by the two samples rather than any bimolecular 
quenching by DOXO on the excited state of NOPD, according to the different localization of these two 
components in the NPs. This is further supported by the almost unaffected spectral changes observed upon 
irradiation in the DOXO spectral region (see Figure 3B) and by the almost unchanged DOXO fluorescence 
after the irradiation (inset Figure 3B).










































Figure 3. (A) NO release profile observed for water suspensions of NP2 (a) and NP1 (b); T = 25 °C; exc = 405 
nm. (B) Absorption spectral changes observed upon 405 nm light irradiation of a water suspension of NP2 for 
irradiation intervals of 0, 4.5, 6, 7.5, 9 and 10.5 min. The inset shows the fluorescence spectra of the NP2 
before (a) and at the end of the irradiation (b).
In-vitro drug release study. Before testing the pharmacological activity of NPs, the release profile of DOXO 
contained in the nanoformulations was evaluated at pH 7.4 (blood pH) and 5.0 (approximate lysosomal pH) 
simulating the body temperature (37 °C). At physiological pH, NP1 and NP3 were very stable, in fact, no DOXO 
release was observed at pH 7.4 in 48 hours. Instead, at pH 5, in the first 24 hours, 4.5 % of the anticancer 
drug was released from NP3, namely 0.34 µg from the initial total cargo of 7.3 µg; after 48 hours the 
hydrolysis percentage of DOXO from the same NPs was doubled (10.6 % released) as shown in Figure S4. The 
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trend was slightly different for the mixed micelle NP1, in fact, while after 24 hours the release percentage 
was around 0.6 %, after 48 hours, DOXO release from NP1 was 5.0 %, namely 0.6 µg from the initial amount 
of 11.6 µg (Figure S4). These results confirmed the high hydrolytic stability of the urea bond and, at the same 
time, the acid responsiveness of the designed nanosystem. We designed this nanoformulation specifically so 
that it would be capable of retaining the drug during circulation in the bloodstream (i.e., pH 7.4), as our prior 
work had shown that stability of drug-polymer linkers was critical to efficacy in mouse cancer models 
following systemic injection.46 We also used the urea linkage as it is sensitive to acidified intracellular 
compartments (endo/lysosomes, pH ca. 5), and because ureas have been evaluated as pro-drugs susceptible 
to overexpressed proteolytic enzymes in anticancer applications previously.47 We therefore evaluated the 
acidic pH triggering of DOXO release as a proxy for the release expected in cell lines and in tumours in-vivo.48
Cell internalization of the NPs. In order to confirm that the designed nanoformulations were able to 
internalize into cancer cells, fluorescent NPs were prepared by combining the two grafted polymers (P1-
DOXO and P1-NOPD in a percentage of 80 %) with a fixed amount (20 %) of the same polymeric backbone 
conjugated to Cyanine-5 (P1-Cy5, see Scheme S1). Three different intrinsically fluorescent NPs were prepared 
by nanoprecipitation as schematically illustrated in Figure S5: NP5, formed by P1-Cy5 and P1-DOXO in a 20/80 
ratio, NP6 consisted of P1-Cy5 and P1-NOPD in a 20/80 ratio and the mixed micelle NP7 formed by P1-Cy5, 
P1-DOXO and P1-NOPD in a 20/40/40 ratio. Incubation of the NPs with lung (A549 adenocarcinoma human 
alveolar basal epithelial), intestine (Caco-2 human colorectal adenocarcinoma cells) and skin (A431 human 
epidermoid carcinoma cells) cancer cell lines, representative cell lines for typical PDT candidate tumours, 
showed internalization of the NPs within 120 minutes as evidenced by the presence of Cy5 fluorescence 
(Figures 4A-C). 
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Figure 4. Micrographs of nanoparticle internalization in (A) A431, (B) A549 and (C) Caco-2 epithelial cells. 
Cells were incubated with nanoparticle solutions (NPs 5-7) at the concentration of 6.5 x 10 µg/mL for 120 
minutes. (i, ii, iii) Enlarged areas highlighted by light boxes.  Scale bar = 30 µm. Images are representative 
from three independent repeats.
In all three figures, it can be noted that the Cy5 signal was located in the cytoplasm with an absence of signal 
in the nuclei of each tested cell line. Further images of the internalized NPs formulations (NP5-7), are 
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separately reported in the supporting information (Figures S6, S7 and S8). In addition to a typically diffuse 
cytoplasmic signal, bright spots of Cy5 signal were noted during NPs imaging, so a co-localization study in 
Caco-2 cells was carried out using a lysosomal stain (Lysotracker green). In these images (Figure 5) the 
superimposition of the Cy5 and lysosomal marker signals demonstrated that there was some degree of 
lysosomal accumulation following internalisation. Taken together, these data suggested receptor-mediated 
endocytosis and trafficking to lysosomes as a possible route of cellular internalization for the mixed-micelle 
formulation (NP7). Such intracellular trafficking has been widely reported for synthetic polymer NPs,49-50 and 
in some cases has been shown to enhance the efficacy of delivered therapeutic agents.51 We thus anticipated 
that the new hybrid mixed-micellar-like NPs would release DOXO effectively, after being internalized and 
trafficked to lysosomes, in accordance with the in-vitro stability study.
Figure 5. Co-localization studies in Caco-2 intestinal cells. Cells were treated with a solution 6.5 x 10 µg/mL 
of NP7 for 120 minutes. Images were processed on Image J software. Cy5 signal of NP7 was false coloured to 
red to aid in visualization of co-localization with green lysosomal signal. White arrows indicate regions of 
green and red overlap. Scale bar = 30 µm.
We also performed flow cytometry experiments. Caco-2 cells exposed to the free drug showed augmented 
fluorescence intensity with increased incubation time (Figure S9A). The incubation time did not affect NP3 
fluorescence intensity, which was lower than the free drug, but significantly higher than the cell 
autofluorescence (Figure S9A). The free drug presented preferable accumulation in the nuclei of the cells, 
with 89% cells showing positive colocalization at 4h, while 20% of cells receiving NP3 showed positive 
colocalization in the same period (Figure S9B). However, the nuclei colocalization of the free drug was 
significantly affected by the increasing incubation times, which had a ~25% reduction at 48h (Figure S9B). 
This fact was further evidenced by confocal images, which revealed accumulation of DOXO in cytoplasmic 
vesicle-like organelles following 48h incubation with the free drug (Figure S10). Notably, NP3 presented 
stable cell uptake and nuclei colocalization at the different time points, whereas the increased incubation 
time significantly affected the performance of the free drug. It was also important to characterize if DOXO 
was preferably inside the cell instead of staining the cell membrane and Figure S9C shows that both the free 
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drug and NP3 showed good intracellular distribution (ratios of internalization above 1.6) in the different time 
points.
In-vitro toxicity. The cytotoxic profiles of NP1 was studied and compared with NPs 2-4 both in the dark and 
under light irradiation against all the previously tested cell types (A549, Caco-2 and A431). In the absence of 
light treatment, NP2 demonstrated no toxicity in the concentration range of 6.5 x 10-4 - 6.5 x 102 µg/mL, as 
illustrated in Figures 6 and 7 (see red line in the Figures), and indicated further by the retention of cellular 
metabolic activity (PrestoBlue assay, Figures 6A-C) and plasma membrane integrity (lactate dehydrogenase 
(LDH) release, Figures 7A-C). In contrast, following light irradiation of 10 minutes’ duration, NO was released, 
with NP2 demonstrating a cell killing effect, observed by both loss of metabolic activity (Figures 6A-C, blue 
line) and the release of LDH (Figures 7A-C, blue line). Assessed via metabolic damage (Figure 6), this effect 
was observed at the lowest concentration tested (6.5 x 10-4 µg/mL). A plateau in this effect was noted 
between 6.5 x 10-4 and 6.5 x 10-1 µg/mL, before an increase in metabolic damage was observed from 6.5 
µg/mL. Determination of IC50 values from metabolic damage revealed that A431 skin cancer cells were the 
most sensitive to light stimulated NOPD toxicity, and Caco-2 intestinal cancer cells were the most resistant 
(Table 3).
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Figure 6. NP2 light (λ = 400 nm, 7 mW cm-2, for 10 min) versus dark effect on cellular metabolic activity by 
the PrestoBlue assay in (A) A431, (B) A549 and (C) Caco-2 cells. NOPD concentration range is 28.4 x 10-6 – 
28.4 µg /mL. Cells were exposed to treatments for a total of 48 hours. Data in graphs represent the mean ± 
S.D. from three independent repeats.
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Formulation IC50 (µg/mL)
 A431 A549 Caco-2
NP2 (Dark) >200 >200 >200
NP2 (Light) 2.5 ± 1.8 4.2 ± 1.3 8.6  ± 2.4
Table 3. Calculated IC50 values by the PrestoBlue assay are for polymer concentration (µg/mL) and presented 
as the mean ± S.E.M.
Interestingly, the release of intracellular LDH, and thus plasma membrane damage, was present at NPs 
concentrations of ≥ 6.5 µg/mL (Figures 7A-C). Therefore, it was possible that the increased cell killing effect 
observed in the highest concentrations (≥ 6.5 µg/mL), following the plateau in metabolic damage, was due 
to both mitochondrial and membrane damage caused by the release of NO.43,44 
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Figure 7. NP2 light (λ = 400 nm, 7 mW cm-2, for 10 min) versus dark effect on the integrity of cell plasma 
membrane by the LDH assay in (A) A431, (B) A549 and (C) Caco-2 cells. NOPD concentration range is 28.4 x 
10-6 -28.4 µg /mL. Cells were exposed to treatments for a total of 48 hours. Data in graphs represent the 
mean ± S.D. from three independent repeats. 
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The photorelease of NO by NP2 (first row Figure 8) and also from the mixed micelle (NP1, second row Figure 
8) in all cell lines tested (A431 in the first column, A549 in the second and Caco-2 cells in the third), following 
irradiation for 10 minutes, was studied using the Griess reaction to detect nitrite. The range of 
concentrations, taken in consideration for each test, of both NPs formulations (NPs 1 and 2) was used also in 
these experiments and the results are reported in Figure 8. The NO release was found to be concentration 
dependent and increased steeply above concentrations of 6.5 µg/mL. 
Figure 8. NO-photorelease in A431 (A), A549 (B) and Caco-2 (C) cells incubated with either NP1 or 2 and either 
maintained in the dark or irradiated (λ = 400 nm, 7mW/cm2), for 10 min. Measurements were performed in 
triplicate and data are presented as means ± SD. Vs untreated cells (ctrl): * p<0.05; ** p<0.01; *** p<0.001.
To investigate the potency and possible enhancement of the chemotherapeutic agent with NOPD, the mixed 
micelles nanoformulation NP1, formed by P1-NOPD and P1-DOXO, was next tested comparing its 
performance against free DOXO and NP3 (Figures 9A-C). 
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Figure 9. Dose-response curves of free DOXO, NP3 and NP 1 both in the dark and light conditions in (A) A431, 
(B) A549 and (C) Caco-2 cells. Data in graphs represent the mean ± S.D. from three independent repeats.
Irradiation conditions were the same (λ = 400 nm, 7 mW cm-2, for 10 min).
From Figure 9, it is apparent that also in this case A549 lung cancer cells (Figure 9B) were the most sensitive 
to the cell killing effect of free DOXO, and Caco-2 cells (Figure 9C) were the most resistant. An increase in 
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DOXO potency was achieved via the conjugation of DOXO to the P1 and the formulation of polymeric NPs. 
These increases in DOXO potency were, again, cell type dependent. In particular, in Caco-2 cells (Figure 9C), 
the efficacy of nanoformulated DOXO was 8 fold higher than free DOXO. Although with different potency, 
this trend was also observed in the other two cellular lines (A459 reported in Figure 9B and A431 cells in 
Figure 9A). These data demonstrate that cancer cells more resistant to DOXO treatment, like Caco-2, may 
benefit the greatest from the nanomedicine approach. The greater efficacy for nanoformulated DOXO 
compared with the free DOXO is probably due to a different internalization pathway and is in good agreement 
with the enhanced activity of anticancer drugs observed in polymer micelles.52,53 
Formulation IC50 (µM)
 A431 A549 Caco-2
Free Doxo 0.7 ± 0.2 0.17  ± 0.02 10.2 ± 2.5
NP3 0.4 ± 0.1 0.07 ± 0.04 1.2  ± 0.2
NP1 (Dark) 0.33 ± 0.03 0.07 ± 0.02 2.0 ± 0.6
NP1 (Light) 0.2 ± 0.10 0.03 ± 0.01 0.4 ± 0.2
Table 4. Calculated IC50 values are for DOXO concentration and presented as the mean ± S.E.M.
In the absence of light irradiation, it was observed that the NP1 formulation displayed similar IC50 values to 
those of NP3 (Table 4); supporting the previous findings shown in Figures 6 and 7 that light stimulation was 
required for the cell toxicity induced by NOPD. It can be noted that under blue light irradiation, the potency 
of NP1 increased by 5.5-, 2.3- and 1.9-fold for Caco-2 (Figure 9C), A549 (Figure 9B) and A431 (Figure 9A) cells, 
respectively, compared to the same formulation in the dark (Figure 9). It can thus be inferred that the 
increased potency with light stimulation was a result of NOPD and its subsequent release of NO. This was 
further confirmed by irradiating NP3 and using the same experimental conditions.  As shown in Figure S11, 
no cytotoxic effect was seen for the non-light-responsive NP3. 
The ultimate comparison of the sequence of formulations tested was between free DOXO solutions and NP1 
following stimulation with light, whereby increases in potency of 27.6-, 5.7- and 3.9-fold were achieved in 
Caco-2 (Figure 9C), A549 (Figure 9B) and A431 (Figure 9A) cells, respectively. Furthermore, to demonstrate 
potential synergism, combination index (CI) values were calculated using the median-effect algorithm 
established by Chou and Talalay54,55 (see experimental) and were based on the potency of NP2 (NOPD-
polymer, with light stimulation), NP3 (DOXO-polymer) and the mixed micelle formulation NP1 (NOPD-
polymer and DOXO-polymer, with light stimulation). Using this method, CI values of 0.40, 0.56 and 0.83 were 
calculated for Caco-2, A549 and A431 cells, respectively. Importantly, all CI values represent an indication of 
synergism (CI<0.9), and that Caco-2 and A549 cells demonstrate strong synergism (CI<0.7),54,55 with the NP1 
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treatment compared to the effects of the constituent polymer formulations alone. This improvement of 
cytotoxic effect thus confirmed that the developed hybrid-mixed-micelle-like NP system not only offered the 
benefit of a temporal control of NO delivery and its therapeutic effect, but it also assured the enhanced 
activity of DOXO in cell lines curable with NO-phototherapy. 
CONCLUSIONS
We have demonstrated how the use of hybrid-mixed-micelle-like NPs can be a valid strategy for the 
enhancement of the antitumor effect of DOXO. In particular, conjugation and formulation of DOXO to 
polymeric NP3 increases itself the activity of the chemotherapeutic drug if compared with the free form, 
confirming that polymeric prodrugs may be adopted as enhancers of active molecules in other 
pharmaceutical and medical applications. This activity is significantly enhanced in the case of the mixed-
nanoformulation (NP1) containing both DOXO and the NOPD due to a combination effect in which the 
increased efficiency of the NO photorelease within the NPs and the slow-release of DOXO play a key role. 
From the data gathered it can be deduced that when applied together, the photoregulated release of NO 
alongside the delivery of DOXO, achieves a synergistic effect that confers an enhanced killing ability of cancer 
cells. To our knowledge, this represents the first example of combination therapy based on 
chemotherateutics and light-stimulated release of NO achieved by using polymer NP formulations. 
Therefore, the present work is a promising proof-of-concept suitable for further in-vivo investigation and, at 
the same time, may open up the field towards the implementation of this type of hybrid-mixed-micellar 
systems in biomedical applications. 
EXPERIMENTAL SECTION
Chemicals. All chemicals were used as obtained without additional purification unless otherwise stated. N,N’-
disuccinimidyl carbonate (DSC, ≥ 95%), poly(ethylene glycol) methyl ether (Mn 5000 Da), 1,8-
diazabicyclo[5.4.0]undec-5-ene (DBU, 98%), triethylamine (TEA, ≥ 99%), di-tert-butyl dicarbonate (99%), 
extra-dry DMSO were purchased from Sigma-Aldrich. 2-amino-1,3-propanediol (Serinol, 98%) and 
dichloromethane (DCM, 99.8%, extra dry over molecular sieve, stabilised, Acroseal) were purchased from 
AcrosOrganics. Trifluoroacetic acid (TFA, 99%) was purchased from VWR Chemicals. Ethylchloroformate was 
purchased from Merck KGaA. Cyanine5 amine (Cy-5) was purchased from Lumiprobe Life Science Solutions. 
All reactions involving air-sensitive reagents were performed under nitrogen using oven-dried glassware and 
the syringe-septum cap technique. Anhydrous sodium sulfate (Na2SO4) was used as the drying agent for the 
organic phase. Organic solvents were removed under reduced pressure at 30 °C. All deuterated solvents used 
for NMR studies were of spectrophotometric grade.
Synthesis. All syntheses, involving NOPD and DOXO, were carried out under a low intensity level of visible 
light. NOPD,39 and P1 were prepared according to previously published protocols.36 1H NMR spectra were 
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recorded on a Bruker 400 MHz spectrometer using CDCl3 or DMSO-d6 as the solvent, as stated. Chemical 
shifts are expressed in parts per million () downfield from the internal standard tetramethylsilane. The 
following abbreviations are used to designate peak multiplicity: s = singlet, d = doublet, dd = doublet of 
doublets; ddd = doublet of doublet of doublets; q = quartet; t = triplet, m = multiplet, bs = broad singlet.
BOC Deprotection Optimisation. A predetermined amount of protected block co-polymer P1 was dissolved 
in extra dry DCM. TFA (5 equivalents in excess compared to repeating tBSC units)56 was added slowly to P1 
mixture at 0 °C. The reaction mixture was left stirring for 6 minutes. Following a first precipitation in cold 
hexane, the resultant material (P1*) was washed with cold diethyl ether and analysed by 1H NMR. NMR 
samples were taken before the addition of TFA, after 6 minutes (before the precipitation) and post 
purification and drying. For simplicity, the 1H NMR spectra before the addition of TFA and after the 
purification and drying process are reported. 1H NMR (t = 0 min) (400 MHz, DMSO-d6) δ = 5.26 – 5.10 (m, 
80H), 4.17 – 4.01 (m, 168H), 3.52 (s, 492H), 1.48 (s, 240H), 1.39 (s, 370H). 1H NMR (post purification and 
drying) (400 MHz, DMSO-d6) δ = 8.42 (bs, 18H), 7.18 – 7.02 (m, 34H), 5.24 – 5.11 (m, 62H), 3.51 (s, 492H), 
1.55 – 1.41 (m, 204H), 1.38 (s, 320H); [14 % deprotection].
NOPD coupling procedure (P1-NOPD). DSC (1.2 eq. with respect to the amount of NOPD, 0.798 mmol, 205 
mg) was added to a solution of NOPD (1.0 eq., 0.665 mmol, 175 mg) dissolved in anhydrous MeCN (5 mL) at 
0 °C. TEA (1.2 eq. with respect to the amount of NOPD, 0.798 mmol, 111 µL) was added slowly to the reaction 
mixture and left stirring for 3 hours. Deprotected polymer P1* (1.0 eq., 0.665 mmol, 120 mg; equivalents 
were calculated to be in varying degrees of excess compared to each repeating tBSC unit) was dissolved in 
anhydrous MeCN (3 mL) and TEA (2.0 eq. with respect to the amount of P1*, 1.33 mmol, 185 µL) was added, 
and the solution was subsequently added dropwise to the previous reaction mixture. The reaction was left 
stirring for a further 3 hours at 0 °C. The resultant conjugated polymer P1-NOPD was purified through 
multiple precipitation steps in cold hexane:diethyl ether:isopropanol mixture and dialysed against 
water:methanol mixture for 24 hours. Finally, the purified aqueous suspension was freeze-dried for 48 hours 
and stored at -22   ͦC. A final NMR spectrum of the product (P1-NOPD) post purification and completely dried 
was recorded. 1H NMR (400 MHz, DMSO-d6) δ = 8.08 (d, J = 9.2 Hz, 10H), 7.06 (bs, 10H), 7.60 -7.55 (m, 16H), 
6.89 – 6.76 (m, 10H), 5.25 – 4.99 (m, 70H), 4.19 – 3.89 (m, 118H), 3.78 (qd, J = 9.9, 6.0 Hz, 40H), 3.51 (s, 492H), 
1.81 – 1.72 (m, 20H), 1.50 – 1.42 (m, 180H), 1.38 (s, 142H). 
Doxorubicin coupling procedure (P1-DOXO). DSC (1.5 eq. with respect to the amount of DOXO, 0.125 mmol, 
32 mg) pre-dissolved in anhydrous MeCN (3 mL) was added to a solution of DOXO (1.0 eq., 0.083 mmol, 48 
mg) in dry DMSO (3 mL) at 0 °C. TEA (2.5 eq. with respect to the amount of DOXO, 0.21 mmol, 30 µL) was 
added slowly to the reaction mixture and left stirring for 4-5 hours. Deprotected polymer P1* (1.0 eq., 0.083 
mmol, 15 mg; equivalents were calculated to be in high excess when compared to each repeating tBSC unit) 
was dissolved in a mixture of anhydrous MeCN/ dry DMSO (50/50, v/v, 3 mL) and TEA (2.0 eq. with respect 
to the amount of P1*, 0.166 mmol, 23 µL) was added, and the solution was subsequently added dropwise to 
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the previous reaction mixture. The reaction was left stirring for a further 3 hours at 0 °C. The resultant 
conjugated polymer P1-DOXO was purified through multiple precipitation steps in cold hexane:diethyl ether: 
isopropanol mixture and dialysed against water:methanol mixture for 24 hours. Finally, the purified aqueous 
suspension was freeze-dried for 48 hours and stored at -22  ͦC. A final NMR spectrum of the product (DOXO-
polymer) post purification and completely dried was recorded. 1H NMR (400 MHz, DMSO-d6) δ = 14.08 (s, 
4H), 7.93 (d, J = 4.3 Hz, 8H), 7.69 – 7.65 (m, 4H), 7.63 (s, 4H), 7.07 (d, J = 7.1 Hz, 21H), 5.34 (d, J = 8.7 Hz, 8H), 
5.24 – 5.11 (m, 78H), 4.86 (d, J = 5.9 Hz, 4H), 4.61 – 4.56 (m, 4H), 4.50 (d, J = 10.1 Hz, 8H), 4.36 (d, J = 4.0 Hz, 
12H), 4.16 – 3.93 (m, 205H), 3.81 – 3.74 (m, 8H), 3.71 – 3.66 (m, 4H), 3.51 (s, 492H), 3.24 (s, 4H), 3.07 – 3.01 
(m, 8H), 2.94 (d, J = 5.9 Hz, 4H), 2.23 (d, J = 3.8 Hz, 4H), 1.50 – 1.41 (m, 200H), 1.38 (s, 290H).
Cy-5 coupling procedure (P1-Cy5). Protected polymer P1 (1.0 eq., 0.005 mmol, 50 mg), TEA (0.5 mL of a stock 
solution prepared by dissolving 30 µL of TEA in 3.0 mL anhydrous MeCN) and DSC (1 mL of a stock solution 
prepared by dissolving 15 mg of DSC in 6 mL anhydrous MeCN) were stirred in a dry glass vial at 0 °C for 3 
hours. Cy5-TEA (1 mL of a stock solution prepared by dissolving 3 mg of Cy5 and 10 µL of TEA in 6 mL of 
anhydrous MeCN) was added to the reaction mixture at 0°C and left for a further for 3 hours. The resultant 
conjugated polymer P1- Cy5 was purified through multiple precipitation steps in cold hexane:diethyl ether 
mixture and subsequently dialysed against water:methanol mixture for 24 hours. Finally, the purified 
aqueous suspension was freeze-dried for 48 hours and stored at -22  ͦC.
Nanoparticle preparation. The nanoprecipitation method was used to form NPs, whereby the grafted 
copolymers were dissolved in acetone at concentrations of either 1 mg/mL or 5 mg/ mL (final concentration 
in water/PBS), according to the biological assay to be performed. The polymeric solution was added at a rate 
of 2 mL/min to either deionized water or PBS, under constant stirring (550 rpm). The polymers rapidly formed 
nanoparticle suspensions through solvent exchange between water and acetone. The final suspension was 
then left stirring for 2 hours and subsequently dialyzed against PBS or water overnight. The same procedure 
was adopted for the fabrication of NP1 (P1-DOXO/P1-NOPD, 50/50, w/w); NP2, (P1-NOPD/P1, 50/50, w/w), 
NP3, (P1-DOXO/P1, 50/50, w/w), NP4, (P1, 100%).
Cy5 micelles for cellular uptake experiments. The nanoprecipitation method was used to form mixed nano-
formulations combining a fixed amount of P1-Cy5 (20%) with functionalized polymer (P1-DOXO, P1-NOPD or 
both, 80%) in order to tune the final fluorescence intensity and maximize both materials usage and detection 
properties (cell uptake and organs biodistribution). The following polymers P1-Cy5/P1-DOXO, P1-Cy5/P1-
NOPD, P1-Cy5/P1-DOXO/P1-NOPD were dissolved in acetone, respecting the abovementioned ratios, at 
concentrations of 1 mg/mL or 5 mg/mL (final concentration in water/PBS), according to the biological assay 
to be performed. The polymeric solution was added at a rate of 2 mL/min to either deionized water or PBS, 
under constant stirring (550 rpm). The polymers rapidly formed coloured-nanoparticle suspensions through 
solvent exchange between water and acetone. The final suspension was then left stirring for 2 hours and 
dialyzed against water or PBS overnight. The same procedure was adopted for the fabrication of NP5, (P1-
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Cy5/P1-DOXO, 20/80, w/w), NP6 (P1-Cy5/P1-NOPD, 20/80, w/w), NP7 (P1-Cy5/P1-DOXO/P1-NOPD, 
20/40/40, w/w).
Physicochemical characterization. The particle size was analyzed by dynamic light scattering (DLS) using a 
Zetasizer Nano ZS (Malvern Instruments Ltd) or a Viscotek 802 DLS with a laser wavelength of 830 nm at 20 
⁰C. Polymer solutions were prepared at 1 mg/mL in PBS. Data was analyzed using OmniSIZE software. A 
minimum of 10 measurements were collected per sample. Measurements from Zetasizer Nano ZS were taken 
in triplicate and used to calculate average intensity particle size distributions. The zeta potential of NPs was 
evaluated according to the electrophoretic mobility of the particles and calculated by the Helmholtz-
Smoluchowsky equation. All measurements were performed in triplicate. Samples were measured on a 
NanoDrop 2000c (Thermo Scientific) for UV or a NanoDrop 3300 (Thermo Scientific) for fluorescence. DOXO 
content in the micelles was calibrated against DOXO standards (λexc= 580 nm, λem= 553 nm) and NOPD content 
in the micelles was calibrated against NOPD standards (λ= 405 nm) using UV. Cy5 content in the mixed 
micelles was calibrated against Cy5-amine standards (λexc = 647 nm, λem = 665 nm) using fluorescence.
In-vitro doxorubicin release study. Drug release studies were performed in phosphate buffer saline (PBS) at 
pH 7.4 (blood pH) and citrate phosphate buffer (0.1 M citric acid, 0.2 M Na2HPO4) at pH 5 (to mimic the 
lysosome pH). A sample (500 µL) of NPs 1 and 3 was placed in a dialysis device (Slide-A-Lyzer mini dialysis 
device, 3.5 K MWCO, Thermo Scientific). The micellar solution was dialyzed against 1.5 mL of release media 
at 37 °C and samples (0.2 mL) were collected at appropriate time points and replaced with the same amount 
of fresh medium to maintain sink conditions. The released DOXO from collected samples was quantified by 
RP-HPLC analysis as previously described.57
Griess assay. NO release was evaluated, as nitrite formed, using the Griess reaction. 5 mL of NPs 1 and 2 
were irradiated using a violet led 10W lamp. An irradiance of 7 mW cm-2 was measured with an HD2302.0 
Delta Ohm light meter equipped with a Delta Ohm LP471RAD light probe. The presence of nitrite was 
determined at regular time intervals using the Griess assay; where 1.0 mL of the reaction mixture was treated 
with 250 µL of Griess reagent (4% w/v sulphanilamide, 0.2 % w/v N-naphthylethylenediamine 
dihydrochloride, 1.47 M phosphoric acid). After 15 min at room temperature, the reaction mixture was 
analysed spectrophotometrically and calibration curves obtained with standard solutions of sodium nitrite 
at 0.5 µM to 50 µM (r2>0.99). The nitrite yield was expressed as amount of NO2- (µg/mL, relative to the initial 
compound concentration) ± SEM.
Instrumentations. UV-Vis spectra absorption were either recorded on a Varian Cary 50BIO UV/Vis 
spectrophotometer (Varian Australia Pty Ltd., Mulgrade, Australia), or on a JascoV-560 spectrophotometer, 
while fluorescence emission spectra were recorded on a Spex Fluorolog-2 (mod. F-111) spectrofluorimeter. 
UV-Vis and fluorescence emission spectra were performed all in air-equilibrated solutions, using quartz cells 
with a path length of 1 cm. Absorption spectral changes were monitored by irradiating the sample in a quartz 
cell (1 cm path length, 3 mL capacity), using a continuum laser with λexc = 405 nm (ca. 100 mW) having a beam 
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diameter of ca. 1.5 mm. Fluorescence lifetimes were recorded with the same fluorimeter equipped with a 
TCSPC Triple Illuminator. The samples were irradiated by a pulsed diode excitation source (Nanoled) at 455 
nm. The kinetics were monitored at 525 nm and each solution itself was used to register the prompt at 455 
nm. The system allowed measurement of fluorescence lifetimes to be carried out from 200 ps. Irradiation of 
the samples in solution was performed in a thermostated quartz cells (1 cm pathlength, 3 mL capacity) under 
gentle stirring, by using a continuum laser with λexc= 405 nm (ca. 100 mW) having a beam diameter of ca. 1.5 
mm.
Direct monitoring of NO release for samples in solution was measured by amperometric detection with a 
World Precision Instrument, ISO-NO meter, equipped with a data acquisition system, and based on direct 
amperometric detection of NO with short response time (< 5 s) and sensitivity range 1 nM – 20 µM. The 
analogue signal was digitalized with a four-channel recording system and transferred to a PC. The sensor was 
accurately calibrated by mixing standard solutions of NaNO2 with 0.1 M H2SO4 and 0.1 M KI according to the 
reaction Equation (6):
4H+ + 2I- + 2NO2- → 2H2O + 2NO + I2
Irradiation was performed in a thermostated quartz cell (1 cm path length, 3 mL capacity) using the 
continuum laser mentioned above at λexc = 405 nm. NO measurements were carried out under stirring with 
the electrode positioned outside the light path in order to avoid NO signal artefacts due to photoelectric 
interference on the ISO-NO electrode. 
Biological experiments
Chemicals. Culture media were supplied by Sigma Chemical Co (St. Louis, MO) and plasticware for cell 
cultures was from Corning (New York, USA). The protein content of cell lysates was assessed with the BCA kit 
from Sigma Chemical Co (St. Louis, MO). Unless otherwise specified, all the reagents were from Sigma 
Chemical Co.
Cells. A431 human epidermoid carcinoma cells, A549 adenocarcinomic human alveolar basal epithelial cells 
and Caco-2 human colorectal adenocarcinoma cells were purchased from the American Type Tissue 
Collection (ATCC) and used at passages 20-30, 30-40 and 35-45, respectively. All cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-Aldrich) supplemented with 10% (v/v) Fetal Bovine 
Serum (FBS; Sigma-Aldrich), 0.1 mg/mL streptomycin, 100 units/mL penicillin, 0.25 µg/mL amphotericin 
(Sigma-Aldrich) and 2 mM L-glutamine (Sigma-Aldrich) at 37 °C with 5% CO2. Cells were seeded at a density 
of 1 x 104 cells per well in 96 well plates (Corning) for 24 hours prior to assaying. Dosing of cells was initiated 
by removing culture medium, washing cells with phosphate buffered saline (PBS; Sigma-Aldrich) and the 
application of 100 µL per well of treatment for 48 hours. Treatment solutions were applied to cells diluted in 
DMEM (no phenol red; Thermo-Fisher) supplemented as described above, however with the lack of 
antibiotics in the medium. Cells were treated with solutions of plain polymeric NPs (NP4), NOPD-conjugated 
polymeric NPs (NP2, at concentrations of 6.5x10-4 to 6.5x102 µg/mL), DOXO-conjugated polymeric NPs (NP3), 
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mixed micelle formulations of NOPD- and DOXO-conjugated polymeric NPs (NP1), or free DOXO (DOXO 
concentrations of 1x10-5 to 1x102 µM). In all in-vitro experiments, treatment with DMEM alone served as the 
negative control and 1.0 % (v/v) Triton X-100 diluted in DMEM as the positive cell death control. When 
indicated, cells were exposed to the light emitted by a 400 nm, 10W LED for 10 minutes, using an irradiance 
of 7 mW cm-2, at room temperature. Non-irradiated cells were maintained in a dark room for 10 minutes at 
room temperature. After light irradiation, cells were incubated for 48 hours at 37 °C with 5% CO2 before the 
assaying described below were applied.
Cytotoxicity testing. Plasma membrane integrity was studied by detecting for released lactate 
dehydrogenase (LDH) in the extracellular environment. Following the incubation with treatments, 75 µL per 
well of supernatant was removed from the treated cells and transferred to a 96 well plate. 150 µL per well 
of LDH detection reagent (TOX7 kit; Sigma-Aldrich) was then added to the samples and the resulting solution 
was incubated at room temperature for 25 minutes in the dark. Absorbance was measured at 492 nm. 
Relative LDH release was calculated by setting the absorbance value of the negative control as 0% and the 
positive control (1.0 % Triton X-100) as 100%. PrestoBlue Cell Viability Reagent (Thermo-Fisher) was used to 
assess the metabolic activity of cells following treatments. Following exposure, treatment solutions were 
removed, cells were washed with PBS and 100 µL per well of 10% PrestoBlue reagent diluted in DMEM (no 
phenol red) was applied to cells for 60 minutes. Solution fluorescence was then measured at 560/600 nm 
(λexc/λem), and relative metabolic activity calculated by setting the values of the negative control as 100% and 
the positive control (1.0% Triton X-100) as 0%.
Determination of combination index (CI) values. CI values were determined according to a widely used 











where DCA represents the IC50 values (based on NOPD concentration) of NP1 (mixed micelles of NOPD-
polymer and DOXO-polymer), and DSA the IC50 (based on NOPD concentration) of NP2 (micelles of NOPD-
polymer). Similarly, DCB represents the IC50 values of (based on DOXO concentration) of NP1 (mixed micelles 
of NOPD-polymer and DOXO-polymer), and DSB the IC50 (based on DOXO concentration) of NP3 (micelles of 
DOXO-polymer). Based on this method, CI values are indicative of strong synergism (<0.7), synergism (0.7-
0.9), additive effect (0.9-1.1), antagonism (1.1-3.3), or strong antagonism (>3.3).54,55
Nitrite release in the cells. The amount of extracellular nitrite was measured spectrophotometrically. Nitrite 
production was measured by adding 12.5 µL of Griess reagent (1:1 solution of 0.2% w/v 
naphthylethylenediamine dihydrochloride, and 2% w/v sulphanilamide in 5% v/v phosphoric acid) to 50 µL 
samples of cell supernatant per well in a 96-well plate. After a 15 min incubation at 37 °C in the dark, 
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absorbance was measured at 540 nm with a Packard EL340 microplate reader (Bio-Tek Instruments, 
Winooski, VT). Sodium nitrite was used as a standard to generate the calibration curve (r2 >0.99). Nitrite 
concentration was expressed as amount of NO2- (µg/mL, relative to the initial nanoparticle concentration) ± 
S.E.M.
Cellular internalization experiments. To investigate cellular uptake, live cell fluorescent microscopy of NPs 
5-7 was performed on Caco-2, A431 and A549 cells. Cells were incubated with nanoparticle solutions for 120
minutes followed by three washes with ice cold PBS to remove particles. Cells were then stained with either
6 µg/mL Hoechst 33342 (Thermo-Fisher) or 6 µg/mL Hoechst 33342 and 100 nM Lysotracker green (Thermo-
Fisher) applied in PBS for 30 minutes. Staining solution was removed and cells washed twice with PBS.
FluoroBrite DMEM media (Thermo-Fisher) was added to wells and cells were imaged on an inverted Nikon
Eclipse TE 300 fluorescent microscope on DAPI and Cy5 filters. Images were merged using Image J software.
Confocal. Caco-2 cells were exposed to NP3 and free drug at 1 µM DOXO for 4/24/48h. Then, cells were 
washed with warm PBS and incubated with Hoechst 33342 nuclei stain (5 µg/mL) for 10 minutes. In sequence, 
the cells were washed with warm PBS and incubated with PBS containing 4% PFA for 15 min at room 
temperature. The preserved cells were washed with warm PBS and kept in PBS. Images were acquired in a 
TCS SPE Leica confocal microscope using 20x objective and the images were analysed using ImageJ software.
Imaging flow cytometry. Caco-2 cells were exposed to NP3 and free drug at 1 µM doxorubicin for 4/24/48h. 
Control samples included cells receiving no treatment and single stain controls (NP3/doxorubicin/Hoechst 
33342). After 4/24/48h incubation time, the treatments  were removed and the cells washed with warm PBS. 
Then, cells receiving Hoechst 33342 nuclei stain were incubated with the dye solution in cell culture media 
(2 µg/mL) for 10 minutes. Cells were washed with warm PBS, detached using trypsin-EDTA solution and 
resuspended in PBS containing 4% PFA. After incubation with the PFA solution for 15 min at room 
temperature, the cells were centrifuged and resuspended in 50 µL PBS. Samples were analysed in an Image 
Streamx Mk II Imaging Flow Cytometer (Amnis®) with 40x magnification. The data analysis was performed in 
an IDEAS® Image Stream Analysis Software (Amnis®).
Statistical analysis. Dose-response curve fitting was performed using non-linear regression analysis to enable 
IC50 determination (GraphPad prism, version 7.03). Statistical analysis was performed by one-way ANOVA 
with Dunnett’s multiple comparison post hoc test using GraphPad Prism.
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Scheme S1. Synthesis of Cy5-polymer. Reagents and conditions: a) DSC, TEA, CH3CN, 0 °C; b) protected 
polymer, TEA, CH3CN, 0 °C.
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Figure S1. Stability of the NP4 in BSA and DMEM at different times.









Figure S2. Absorption spectrum of NP2 (a) and, for comparison the free NOPD (b) in water.
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Figure S4. DOXO release profile observed after 48 h from NP1 (0.81 mg/mL) and NP3 (0.73 mg/mL) at pH 5.0 
lysosome mimicking.
(A) (B)
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Figure S5. Schematic illustration of NPs 5-7.
Figure S6. Micrographs of nanoparticle internalization in A431 cells. Cells were incubated with nanoparticle 
solutions (NPs 5-7) at the concentration of 6.5 x 10 µg/mL for 120 minutes. Scale bar = 30 µm. Images are 
representative from three independent repeats.
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Figure S7. Micrographs of nanoparticle internalization in A549 cells. Cells were incubated with nanoparticle 
solutions (NPs 5-7) at the concentration of 6.5 x 10 µg/mL for 120 minutes. Scale bar = 30 µm. Images are 
representative from three independent repeats.
Figure S8. Micrographs of nanoparticle internalization in Caco-2 cells. Cells were incubated with nanoparticle 
solutions (NPs 5-7) at the concentration of 6.5 x 10 µg/mL for 120 minutes. Scale bar = 30 µm. Images are 
representative from three independent repeats.
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Figure S9. Median doxorubicin fluorescence intensity of NP3 and free drug at increasing time points (A). Ratio 
of doxorucin nuclei colocalization with Hoechst nuclei dye and percentage of cells with positive nuclei 
colocalization (B). Caco-2 cells were incubated with NP3 and free drug at 1 µM doxorubicin for 4/24/48h 
(n=3). Representative images of nuclei colocalization and internalization and histograms of doxorubicin 
fluorescence intensity, colocalization and internalization for 4, 24 and 48h incubation times.  Data was 
acquired in a ImageStream Flow Cytometer and analysed using IDEAS software (v. 6.2, Amnis). 
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Figure S10. Confocal images of NP3 and free drug uptake at 1 µM doxorubicin following 4/24/48 h incubation. 
Bar represents 50 µM and 25 µM (zoomed images).
Figure S11. NP3 effect potency. Cells were exposed to NP3 for 48 hours either in the dark or under irradiation 
(λ = 400 nm, 7 mW cm-2, for 10 min). Metabolic activity was assessed using the PrestoBlue assay. Data 
represents the mean ± S.D. (n=3).
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